Valuation: Novavax, Inc.

Market Cap 1.23B 1.08B 1B 919M 1.73B 118B 1.75B 11.9B 4.65B 58.08B 4.61B 4.51B 201B P/E 2026 *
-15.8x
P/E 2027 * -29.3x
Enterprise Value 1.45B 1.27B 1.18B 1.08B 2.04B 139B 2.07B 14.02B 5.48B 68.45B 5.43B 5.31B 237B EV / Sales 2026 *
3.53x
EV / Sales 2027 * 5.92x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
1 day-4.66%
1 week-9.14%
Current month-20.81%
1 month-12.85%
3 months-9.25%
6 months-18.65%
Current year+11.01%
1 week 7.45
Extreme 7.45
8.3
1 month 7.45
Extreme 7.45
10.12
Current year 6.76
Extreme 6.76
11.97
1 year 6.2
Extreme 6.2
11.97
3 years 3.53
Extreme 3.5324
23.86
5 years 3.53
Extreme 3.5324
277.8
10 years 3.53
Extreme 3.5324
331.68
Manager TitleAgeSince
Chief Executive Officer 59 2023-01-22
Director of Finance/CFO 60 2021-08-15
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 73 2010-08-05
Director/Board Member 66 2018-10-31
Director/Board Member 60 2020-06-15
Date Insider Type Main position Quantity % Market Cap.
6/20/26 Fiscal year

Chairman

37,760 0.0230%
6/20/26 Fiscal year

Director

37,760 0.0230%
6/20/26 Fiscal year

Director

37,760 0.0230%
Change 5-day change 1-year change 3-year change Capi.($)
-4.66%-9.14%-0.13%-6.75% 1.23B
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average -0.26%-0.17%+48.49%+93.86% 24.65B
Weighted average by Cap. +0.45%+0.86%+74.02%+135.51%

Financials

2026 *2027 *
Net sales 410M 360M 335M 307M 577M 39.48B 586M 3.98B 1.55B 19.41B 1.54B 1.51B 67.11B 258M 227M 211M 194M 364M 24.89B 370M 2.51B 979M 12.24B 970M 949M 42.31B
Net income -79.31M -69.65M -64.78M -59.44M -112M -7.64B -113M -769M -301M -3.75B -298M -291M -12.98B -43.22M -37.96M -35.3M -32.4M -60.87M -4.16B -61.81M -419M -164M -2.05B -162M -159M -7.08B
Net Debt 219M 192M 179M 164M 308M 21.09B 313M 2.12B 830M 10.37B 822M 804M 35.85B 303M 266M 248M 227M 427M 29.2B 434M 2.94B 1.15B 14.36B 1.14B 1.11B 49.64B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
749
Date Price Change Volume
26-07-24 US$7.460 -4.66% 3,178,300
26-07-23 US$7.825 -1.07% 2,389,394
26-07-22 US$7.910 -2.04% 2,637,232
26-07-21 US$8.075 +2.47% 2,530,269
26-07-20 US$7.880 -4.02% 3,029,402
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
7.460USD
Average target price
14.11USD
Spread / Average Target
+89.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVAX Stock